{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:10Z","timestamp":1791903310568,"version":"4.3.4"},"reference-count":39,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>B-cell maturation antigen (BCMA)\u2013targeted therapies have emerged as promising treatment options for patients with relapsed\/refractory immunoglobulin light-chain (AL) amyloidosis. However, comprehensive data on their efficacy and safety remain limited. We conducted a systematic descriptive pooled analysis of published studies reporting outcomes of BCMA-directed therapies including chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). The analysis included 256 patients. CAR-T therapy was administered to 89 patients (35%), BsAbs to 82 patients (32%), and ADCs to 85 patients (33%). The pooled overall response rate (ORR) was 83%, with CAR-T demonstrating 92% ORR; BsAbs, 89%; and ADCs, 68%. Deep hematologic responses (\u2265very good partial response) were achieved in \u223c70% of CAR-T and BsAb recipients and 64% of ADC recipients. Minimal residual disease negativity was documented in 75% of evaluable CAR-T patients and in 86% of evaluable BsAb patients with reported data. Organ responses were observed in 30% of evaluable patients, with cardiac responses in 41%. Cytokine release syndrome (CRS) occurred in 74% of CAR-T and 49% of BsAb patients, predominantly grade 1 to 2. Grade \u22653 CRS was rare (9% in CAR-T and 1% in BsAb). Ocular toxicity was the predominant adverse event in ADC recipients (84% with any grade and 29% with grade \u22653). Grade \u22653 infections occurred in 13% of CAR-T, 20% of BsAb, and 6% of ADC patients. BCMA-targeted therapies result in high response rates with manageable safety profiles among patients with heavily pretreated AL amyloidosis, supporting continued investigation and clinical application of these approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020740","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:51:37Z","timestamp":1784634697000},"page":"6435-6443","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis"],"prefix":"10.1182","volume":"10","author":[{"given":"Raghad","family":"Alqazaqi","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Corewell Health System, Dearborn, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-0120","authenticated-orcid":false,"given":"Sean","family":"Taasan","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-6316","authenticated-orcid":false,"given":"Adeel M.","family":"Khan","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Faizan","family":"Zahid","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"4Myeloma Program, Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"4Myeloma Program, Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"5Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"2Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"24","key":"2026101310421024100_bib1","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026101310421024100_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026101310421024100_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026101310421024100_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026101310421024100_bib5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026101310421024100_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026101310421024100_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration progression-free survival results from the phase 3 ANDROMEDA study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"key":"2026101310421024100_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/OTT.S370880","article-title":"Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives","volume":"16","author":"Shrivastava","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"8","key":"2026101310421024100_bib9","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","article-title":"Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies","volume":"32","author":"Al Hadidi","year":"2024","journal-title":"Mol Ther"},{"issue":"8","key":"2026101310421024100_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"2026101310421024100_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2026101310421024100_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026101310421024100_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2026101310421024100_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjh.19960","article-title":"Update on B-cell maturation antigen-directed therapies in AL amyloidosis","volume":"206","author":"Jamroziak","year":"2025","journal-title":"Br J Haematol"},{"key":"2026101310421024100_bib15","unstructured":"Development Core Team\n          . R A Language and Environment for Statistical Computing. Accessed 27 July 2026. https:\/\/cran.r-project.org\/doc\/manuals\/r-release\/fullrefman.pdf."},{"issue":"17","key":"2026101310421024100_bib16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026101310421024100_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ejh.14293","article-title":"Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis","volume":"113","author":"Goel","year":"2024","journal-title":"Eur J Haematol"},{"issue":"12","key":"2026101310421024100_bib18","doi-asserted-by":"crossref","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2026101310421024100_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2025-696","article-title":"First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R\/R light chain (AL) amyloidosis, NXC-201","volume":"146","author":"Landau","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101310421024100_bib20","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2025-2181","article-title":"The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis","volume":"146","author":"Rees","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026101310421024100_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/bloodadvances.2025017488","article-title":"AL amyloidosis: a real-world experience with CAR T-cell therapy","volume":"10","author":"Tan","year":"2026","journal-title":"Blood Adv"},{"issue":"16","key":"2026101310421024100_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026101310421024100_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026101310421024100_bib24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jha2.772","article-title":"First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma","volume":"4","author":"Leung","year":"2023","journal-title":"eJHaem"},{"issue":"3","key":"2026101310421024100_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.14348","article-title":"Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis","volume":"114","author":"Stalker","year":"2025","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2026101310421024100_bib26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2025-692","article-title":"Phase 1\/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026101310421024100_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.70140","article-title":"","volume":"101","author":"Rees","year":"2026","journal-title":"Am J Hematol"},{"issue":"9","key":"2026101310421024100_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","article-title":"High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"12","author":"Khwaja","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026101310421024100_bib29","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/bjh.19286","article-title":"Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"204","author":"Khwaja","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"2026101310421024100_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000541594","article-title":"Belantamab mafodotin in relapsed\/refractory AL amyloidosis: real-world multi-center experience and review of the literature","volume":"148","author":"Lebel","year":"2025","journal-title":"Acta Haematol"},{"issue":"suppl 3","key":"2026101310421024100_bib31","first-page":"e967704","article-title":"Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the European Myeloma Network [abstract]","volume":"7","author":"Kastritis","year":"2023","journal-title":"HemaSphere"},{"issue":"9","key":"2026101310421024100_bib32","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-022-04890-z","article-title":"Belantamab mafodotin in patients with relapsed\/refractory AL amyloidosis with myeloma","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann Hematol"},{"issue":"11","key":"2026101310421024100_bib33","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.3390\/curroncol30110697","article-title":"Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed\/refractory multiple myeloma: preliminary efficacy and safety","volume":"30","author":"Das","year":"2023","journal-title":"Curr Oncol"},{"issue":"8","key":"2026101310421024100_bib34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101310421024100_bib35","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1182\/blood-2023-182971","article-title":"Teclistamab induces rapid responses in patients with relapsed\/refractory AL amyloidosis","volume":"142","author":"Mann","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026101310421024100_bib36","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2026101310421024100_bib37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"17","key":"2026101310421024100_bib38","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"35","key":"2026101310421024100_bib39","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6435\/2590634\/blooda_adv-2026-020740-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6435\/2590634\/blooda_adv-2026-020740-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:42:21Z","timestamp":1791902541000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6435\/569776\/Efficacy-and-safety-of-BCMA-targeted-therapies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":39,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020740","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,24]]}}}